惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Threat Intelligence Blog | Flashpoint
Threat Intelligence Blog | Flashpoint
D
Darknet – Hacking Tools, Hacker News & Cyber Security
N
News and Events Feed by Topic
N
News | PayPal Newsroom
SecWiki News
SecWiki News
P
Privacy International News Feed
T
Troy Hunt's Blog
Attack and Defense Labs
Attack and Defense Labs
N
News and Events Feed by Topic
L
LINUX DO - 热门话题
www.infosecurity-magazine.com
www.infosecurity-magazine.com
Security Latest
Security Latest
AWS News Blog
AWS News Blog
S
Secure Thoughts
W
WeLiveSecurity
H
Heimdal Security Blog
T
Threat Research - Cisco Blogs
I
Intezer
Application and Cybersecurity Blog
Application and Cybersecurity Blog
S
Security @ Cisco Blogs
G
GRAHAM CLULEY
cs.CV updates on arXiv.org
cs.CV updates on arXiv.org
Spread Privacy
Spread Privacy
L
Lohrmann on Cybersecurity
C
CERT Recently Published Vulnerability Notes
S
Security Affairs
Hacker News - Newest:
Hacker News - Newest: "LLM"
Google Online Security Blog
Google Online Security Blog
Cisco Talos Blog
Cisco Talos Blog
雷峰网
雷峰网
Cloudbric
Cloudbric
Y
Y Combinator Blog
酷 壳 – CoolShell
酷 壳 – CoolShell
博客园_首页
Hacker News: Ask HN
Hacker News: Ask HN
cs.AI updates on arXiv.org
cs.AI updates on arXiv.org
Google DeepMind News
Google DeepMind News
Vercel News
Vercel News
云风的 BLOG
云风的 BLOG
Latest news
Latest news
CTFtime.org: upcoming CTF events
CTFtime.org: upcoming CTF events
D
Docker
Recent Announcements
Recent Announcements
博客园 - 【当耐特】
H
Help Net Security
博客园 - 司徒正美
TaoSecurity Blog
TaoSecurity Blog
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
C
Check Point Blog
博客园 - 叶小钗

Vox

Vox Vox Vox Vox Vox Vox Trump says Cuba is “next.” What does that mean? What twins can teach us about friendship Trump’s next redistricting targets Graham Platner’s triumph, explained by a Maine reporter A major new study found AI outperformed doctors in ER diagnosis — but there’s a catch What China is learning from the US war in Iran The surprising reason why buying guns helps endangered species Why “neighborism” is having a moment This is what it takes to become Trump’s attorney general The Voting Rights Act is all but dead. Prepare for maximum gerrymandering. Activists tried to free 2,000 dogs bred for lab research in Wisconsin. Then came the tear gas. The sad, ugly debate behind the new Michael Jackson biopic We’re missing the economic fallout of the Iran war — just like we did with Covid Why famous people want to be death doulas This billionaire could be California’s next governor — and he wants to arrest Stephen Miller What really happened after Trump slashed HIV funding What haunts America’s animal shelter workers James Comey gets indicted (again) The numbers on US political violence MAHA wellness culture is coming for teens. Grown-ups aren’t ready. Renewable energy just broke a 100-year-old streak What Trump wants out of the Correspondents’ Dinner shooting The Supreme Court seems nervous about letting the police track you with your phone Has Lena Dunham changed? Have we? The great 2028 Olympic ticket crashout, explained Democrats’ latest critique of Walmart is wrong — and dangerous The surprising reason why pedestrian deaths are down in the US Welcome to the May issue of The Highlight Should you feel guilty for killing the bugs in your house? What we know about the shooting at the White House Correspondents’ Dinner Caregiving has a burnout problem 5 of your biggest questions about the Iran war, answered Why colleges are going out of business How charities should handle the next Jeffrey Epstein Live Nation lost. Will anything change for ticket prices? Are the latest Iran talks for real? Can Mayor Mamdani get Democrats back on track? Why America’s HIV epidemic hasn’t ended The 1980s sex scandal that explains TMZ’s move to DC The real problem with Hasan Piker The return of resistance crafting The most successful health campaign in modern history Nobody is laughing at Donald Trump anymore Trump’s big marijuana move Please don’t inject yourself with bootleg peptides Am I the bad friend? Democrats are winning the redistricting war — for now, anyway Yes, you need “me time.” Here’s how to do it right. The next global Trump ally to fall? Trump’s cruel plan for Afghan refugees, briefly explained The wide-ranging fallout from the Supreme Court’s new terrorism decision, explained The best thing you can do for the planet on Earth Day What happens when a tradwife has to put her money where her mouth is Why are states unleashing millions of these fish? Anthropic just made AI scarier Another Trump official exits in scandal Want to fight climate change effectively? Here’s where to donate your money. The Supreme Court will decide if migrants can be sent back to war zones The fight for paid parental leave is more winnable than you think Virginia voters just handed Democrats another win in the Great Redistricting Wars Why the Pentagon is dropping a flu vaccine mandate The war in Iran isn’t ending — it’s becoming something new The diabolical, millennial obsession with chicken Caesar wraps Can you profit off nature without destroying it? These venture capitalists are betting on it. Is it wrong to send your kid to private school? What do we lose when we erase ugliness? RFK Jr. is in his influencer era The lucky few who can apply for tariff refunds How to make unemployment suck a little less The Supreme Court will decide when the police can use your phone to track you Israel’s critics are winning the battle for the Democratic Party Is “time confetti” ruining parenthood? What to do about burnout at work Rubén Gallego on why he defended Eric Swalwell — and why he regrets it now The simple question that could change your career How Americans really feel about immigration Is the Strait of Hormuz really open? An expert forecasts how the Iran war could hit your budget Live Nation lost in court. Here’s what it means for concerts. How to ask for help when you’re really going through it Trump’s ceasefire announcement, briefly explained What to know about the Israel-Lebanon conflict The alcohol crisis quietly hitting high-stress, “high-status” workers Trump’s bungled Iran negotiations didn’t have to go this way Trump’s DOJ wants to undo January 6 convictions Donald Trump messed with the wrong pope 8 ways to zone out and relax that don’t involve being on your phone Why Americans can’t escape credit card debt A cautionary tale about tax cuts The tax code rewards generosity. But probably not yours. Obama’s top Iran negotiator on Trump’s screwups The case for AI realism The new Hormuz blockade, briefly explained Why inflation is up
We’re not as helpless against dementia as we think
Bryan Walsh · 2026-06-15 · via Vox

I turned 48 this week, which meant it was time for my annual physical. After the usual battery of questions from my doctor — How much did I drink? Was I exercising? How was I sleeping? — it was my turn to ask a question. I had one prepared: Should I get the shingles vaccine?

Good News

A weekly dose of stories chronicling progress around the world.

Key takeaways

  • Dementia cases will keep climbing as the population ages — a projected million new US cases annually by 2060 — but your odds of getting it at any given age have been falling for decades. An 80-year-old today is meaningfully less likely to have dementia than one a generation ago.
  • Across wealthy countries, age-specific dementia rates have dropped roughly 13 percent per decade since the late 1980s, and most of that decline tracks with things we can influence: better-controlled blood pressure and cholesterol, less smoking, more years of school. The brain lives downstream of the heart.
  • A 2024 Lancet commission estimated that up to 45 percent of dementia could be prevented or delayed by addressing 14 risk factors — and the highest-leverage window is midlife, not old age.
  • The anti-dementia to-do list: treat your blood pressure and LDL cholesterol, don’t smoke, stay physically active, get your hearing and vision checked, keep learning, and go easy on alcohol. Unglamorous, but it buys time for your brain.
  • A growing run of studies links the shingles vaccine to lower dementia risk. The evidence isn’t conclusive and the shot is only recommended at 50, but it’s worth a conversation with your doctor.
  • There is no drug that reverses dementia today. That’s not the same as being helpless.

According to standard medical guidance, the answer would be no. The shingles vaccine is only recommended by the government for people 50 years or older; the only exceptions are adults whose immune systems are weakened by disease or treatment. And despite the way my back feels when I get out of bed each morning, I wasn’t there quite yet. Our immune systems weaken as we age, but at 48, I was probably still capable of beating back the varicella-zoster virus that causes shingles (and chickenpox).

And yet my doctor was open to the idea for the same reason that I was asking about it: because there is early but growing evidence that the shingles vaccine may be protective against neurodegenerative diseases like dementia. For someone my age, with more time behind me than in front of me, the possibility of developing those diseases — and the desire to do anything to prevent them — is suddenly looming large.

I’m far from alone. Dementia already afflicts more than 6 million Americans today, and a 2025 study in Nature Medicine estimated that the lifetime risk of developing dementia after age 55 is 42 percent, with higher figures for women, Black adults, and those who carry the APOE ε4 allele genetic variant, which is known to increase the risk for Alzheimer’s. That same study projected new US cases of dementia would double by 2060, from 514,000 a year in 2020 to more than 1 million annually, due largely to population aging.

Behind those figures is a universe of suffering. Nearly everyone reading this has watched, or will watch, someone they love succumb to dementia. And once you get to my side of your 40s, that risk starts to feel less abstract and a lot more personal.

Yet the frightening story of the rise in dementia cases as the US population ages obscures real progress that is already being made to prevent it — and the even greater progress that could follow. Dementia may feel inevitable, a cruel side effect of longer life. But it doesn’t have to be.

Dementia epidemiology 101

The Nature study is about incidence — new cases, not the total number of people living with dementia. Separate CDC estimates project nearly 14 million older Americans living with Alzheimer’s disease, the most common form of dementia, by 2060.

But the rate hasn’t been holding steady — it’s been dropping. A 2020 study that drew on data from six countries across Europe and North America found that age-specific dementia incidence for people of European ancestry had fallen about 13 percent per decade since the late 1980s, and around 16 percent per decade for clinical Alzheimer’s. A 2016 study tracked five-year dementia rates across four periods between the late 1970s and the early 2000s and found them steadily falling, ultimately dropping 44 percent by the most recent period. The authors of the 2020 study project that if the decline in incidence remains steady in the future, 15 million fewer people might develop dementia by 2040 across high-income countries than if the incidence of the disease remained unchanged.

That good news may not be shared by everyone. The 2016 study found that the decline only showed up among people with at least a high school diploma — more on that below — and even then, it wasn’t evenly shared. And the sheer increase in older people means that a continually dropping incidence only blunts the coming dementia wave, rather than blocking it. One study of older adults in England actually found dementia incidence falling through 2008 and then creeping back up; the researchers also found that when you account for the fact that people headed toward dementia tend to die earlier, the drop gets much harder to see. What’s fallen before can rise again.

But what this likely means in practice is that a person turning 80 today is meaningfully less likely to have dementia than a person who turned 80 a generation ago. And it’s reasonable to hope the same will hold for whoever turns 80 next — like, say, me.

The question, though, is why.

How we learned to fight dementia without realizing it

Here’s a veteran health journalist tip: if anyone ever asks you why something is improving in public health, just attribute it to the decline in smoking. There’s a decent chance you’ll be right.

While Alzheimer’s is a brain disease, and dementia is the umbrella term for several kinds of cognitive decline, there is a growing consensus that they are deeply driven by vascular health — meaning what damages your heart and blood vessels is ultimately what damages your mind. Thanks to the development of blood pressure and cholesterol-lowering medicines, better heart disease and stroke management, and perhaps most of all, drastic reductions in smoking, cardiovascular health has been improving. Even with the rise of obesity and diabetes, most vascular risk factors have decreased over the same time that dementia and Alzheimer’s prevalence fell.

The rise in education over the same time period may play a role as well. Americans turning 80 today went to school during a great mid-century expansion in education, while their parents were schooled — or rather, not schooled — in the 1920s and ’30s. In 1940, only 24.5 percent of Americans 25 and older had a high school diploma, and just 4.6 percent had completed a bachelor’s degree or more. By 2017, high school completion had reached 90 percent, and the share of people with a bachelor’s or more had hit 34 percent. And researchers have correlated higher education attainment with lower dementia and Alzheimer’s rates.

Now repeat after me: correlation is not causation. Researchers don’t really know why more years of schooling seem to be associated with a lower risk of dementia, though there are theories that education might boost the brain’s “cognitive reserve.” But the hopeful take is that the decline in incidence is largely driven by behaviors and life conditions we can change. And one of the most unexpected and promising acts is something as simple as routine vaccination.

The vaccine you need to know about

Last April, I wrote about what I called “one of the brightest spots in an otherwise dark field”: a study in Wales that found that older adults who received a vaccine against shingles were 20 percent less likely to develop dementia in the seven years following vaccination than those who did not receive it. It wasn’t a randomized trial, but it was stronger than the usual observational association: the study harnessed a natural experiment in Wales, where vaccine eligibility turned on a birthday cutoff, meaning it was less likely that the results were because vaccinated people were simply healthier.

Earlier this year, a study in Canada looked at hundreds of thousands of people over the age of 70 and, like the Welsh study, found that those who had taken the shingles vaccine were less likely to develop dementia. And a new analysis from late 2025 of the data in the Welsh study found that the vaccine was associated with benefits that went beyond prevention — it also seemed to slow the disease for those with dementia and reduced deaths attributable to it.

The shingles vaccine in the Welsh study was an older, live-virus version; the current vaccine is a newer recombinant form that can’t accidentally cause shingles, and another study found it was associated with even greater protection from dementia.

These findings are promising but still leave plenty of questions. The Welsh live-vaccine study found a larger apparent benefit in women, who also suffer higher rates of dementia. But the pattern is not settled: the newer recombinant-vaccine study found an association in both men and women, though stronger in women. Shingles may be connected to dementia, though the evidence is still messy: A large 2025 health-records study found recurrent shingles was associated with a modestly higher dementia risk than a single episode, while earlier evidence has been more mixed.

Shingles occurs when the dormant varicella zoster virus — the same virus that causes chickenpox — reactivates. It’s possible that the resulting neural inflammation may feed dementia. A randomized controlled trial published in December tested a related herpes-virus idea, treating 120 adults with early Alzheimer’s or mild cognitive impairment — all with evidence of prior herpes simplex infection — with a medication called valacyclovir. After 18 months, researchers found no significant advantage over a placebo, dampening hopes that herpes antivirals could be an effective Alzheimer’s treatment.

That’s a real strike against the simplest version of the theory that the virus itself is rotting the brain. But it could mean that the shingles vaccine’s possible protective effects don’t come from shingles at all. A 2025 study found that the newer shingles vaccine and an RSV vaccine that share the same AS01 immune-boosting adjuvant were each associated with lower 18-month dementia risk compared with flu vaccination, and researchers did not find a statistically significant difference between the two AS01 vaccines. The implication is that the benefit might come from giving an aging immune system a jolt, rather than from any one bug it’s aimed at.

You can protect yourself

But as the vaccine science sorts itself out, there are lifestyle changes you can make to help protect yourself without getting a shot. A 2024 Lancet commission found that, in principle, up to 45 percent of dementia cases could be prevented or delayed by addressing 14 risk factors, including not smoking; lowering high LDL cholesterol in midlife; treating hearing loss, especially from midlife on; and limiting obesity. The key period here is midlife, which the commission defined (rather widely in my opinion) as 18-65. Which, for someone my age, means there’s no better time to focus on prevention.

I don’t know whether I’ll go ahead and try to get the shingles vaccine early, and to be clear, I’m not telling anyone they should. The science is still uncertain, and I am, obviously, not a medical doctor. But the lifestyle factors that have been shown to protect against dementia — which are largely the same ones that help cardiovascular health — can be adopted by everyone, for their health now and in the future.

No one knows for sure what the future holds, for me or for you. What’s certain is that, barring a medical miracle, the sheer number of dementia cases will continue to rise as our population ages, and that some of us will be in that number. But that doesn’t mean we’re helpless.

A version of this story originally appeared in the Good News newsletter. Sign up here!